146 related articles for article (PubMed ID: 21248618)
1. PharmGKB summary: voriconazole pathway, pharmacokinetics.
Barbarino JM; Owusu Obeng A; Klein TE; Altman RB
Pharmacogenet Genomics; 2017 May; 27(5):201-209. PubMed ID: 28277330
[No Abstract] [Full Text] [Related]
2. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Hoenigl M; Arastehfar A; Arendrup MC; Brüggemann R; Carvalho A; Chiller T; Chen S; Egger M; Feys S; Gangneux J-P; Gold JAW; Groll AH; Heylen J; Jenks JD; Krause R; Lagrou K; Lamoth F; Prattes J; Sedik S; Wauters J; Wiederhold NP; Thompson GR
Clin Microbiol Rev; 2024 Jun; 37(2):e0007423. PubMed ID: 38602408
[TBL] [Abstract][Full Text] [Related]
3. Environmental surveillance of fungi and susceptibility to antifungal agents in tertiary care hospitals.
Badiee P; Ghadimi-Moghadam A; Bayatmanesh H; Soltani J; Salimi-Khorashad AR; Ghasemi F; Amin Shahidi M; Jafarian H
Microbiol Spectr; 2024 Jan; 12(1):e0227023. PubMed ID: 38047700
[TBL] [Abstract][Full Text] [Related]
4. New trends in antifungal treatment: What is coming up?
Guinea J
Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):59-63. PubMed ID: 37997874
[TBL] [Abstract][Full Text] [Related]
5. Advancements and challenges in antifungal therapeutic development.
Puumala E; Fallah S; Robbins N; Cowen LE
Clin Microbiol Rev; 2024 Mar; 37(1):e0014223. PubMed ID: 38294218
[TBL] [Abstract][Full Text] [Related]
6. What Is New in Fungal Infections?
Parsons MG; Diekema DJ
Mod Pathol; 2023 Jun; 36(6):100187. PubMed ID: 37059227
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine repositioning: A review of potential alternative antifungal therapy.
Spadari CC; Borba-Santos LP; Rozental S; Ishida K
J Mycol Med; 2023 Nov; 33(4):101436. PubMed ID: 37774486
[TBL] [Abstract][Full Text] [Related]
8. Antifungal drug development: challenges, unmet clinical needs, and new approaches.
Roemer T; Krysan DJ
Cold Spring Harb Perspect Med; 2014 May; 4(5):. PubMed ID: 24789878
[TBL] [Abstract][Full Text] [Related]
9. Repurposing drugs for fungal infections: advantages and limitations.
Almeida-Paes R; Frases S
Future Microbiol; 2023 Nov; 18():1013-1016. PubMed ID: 37721174
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of invasive fungal infections in the mediterranean area.
Binder U; Lass-Flörl C
Mediterr J Hematol Infect Dis; 2011; 3(1):e20110016. PubMed ID: 21625305
[TBL] [Abstract][Full Text] [Related]
11. Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish.
Wurster S; Ruiz OE; Tatara AM; Kontoyiannis DP; Eisenhoffer GT
STAR Protoc; 2021 Dec; 2(4):100963. PubMed ID: 34849488
[TBL] [Abstract][Full Text] [Related]
12. Resistant fungal infection: a matter of importance not only in critical COVID patients.
Seijas Betolaza I; Higuera Lucas J; Barrios Andres JL; López Soria LM; Boado Varela V
Minerva Anestesiol; 2024 Mar; 90(3):213-214. PubMed ID: 37987994
[No Abstract] [Full Text] [Related]
13. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.
Epstein DJ; Seo SK; Brown JM; Papanicolaou GA
J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i60-i72. PubMed ID: 29304213
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia.
Gomes MZ; Jiang Y; Mulanovich VE; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 May; 58(5):2775-80. PubMed ID: 24590477
[TBL] [Abstract][Full Text] [Related]
15. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
16. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
Lewis RE
Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
[TBL] [Abstract][Full Text] [Related]
17. Emerging moulds: epidemiological trends and antifungal resistance.
Miceli MH; Lee SA
Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
19. Changing epidemiology of systemic fungal infections.
Richardson M; Lass-Flörl C
Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
